Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice

International Journal of Cancer

Volumn 77, Issue 6, 1998, Pages 937-941

  Lollini, Pier Luigi ^a,d   Nicoletti, Giordano ^a   Landuzzi, Lorena ^a   De Giovanni, Carla ^a   Rossi, Ilaria ^a   Di Carlo, Emma ^b   Musiani, Piero ^b   Muller, William J ^c   Nanni, Patrizia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c MCMASTER UNIVERSITY   (Canada)

^d Istituto di Cancerologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; RECOMBINANT GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; LONG TERMINAL REPEAT; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; CARCINOMA; DNA PRIMERS; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; INTERFERON TYPE II; MAJOR HISTOCOMPATIBILITY COMPLEX; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2;

EID: 0031870766     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980911)77:6<937::AID-IJC24>3.0.CO;2-X     Document Type: Article

References (21)

1. ALGARRA, I., OEHLEN, C., PEREZ, M., LJUNGGREN, H.-G., KLEIN, G., GARRIDO, F. and KÄRRE, K., NK sensitivity and lung clearance of MHC-class-I-deficient cells within a heterogeneous fibrosarcoma. Int. J. Cancer, 44, 675-680 (1989).
2. DE GIOVANNI, C., PALMIERI, G., NICOLETTI, G., LANDUZZI, L., SCOTLANDI, K., BONTADINI, A., TAZZARI, P.-L., SENSI. M., SANTONI, A., NANNI, P. and LOLLINI, P.-L., Immunological and nonimmunological influence of H-2Kb gene transfection on the metastatic ability of B16 melanoma cells. Int. J. Cancer, 48, 270-276 (1991).
3. DISIS, M.L. and CHEEVER, M.A., HER-2/neu protein: a target for antigen- specific immunotherapy of human cancer. Adv. Cancer Res., 71, 343-371 (1997).
4. DISIS, M.L., PUPA, S.M., GRALOW, J.R., DITTADI, R., MENARD, S. and CHEEVER, M.A., High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. clin. Oncol., 15, 3363-3367 (1997).
5. FERRONE, S. and MARINCOLA, P.M., Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today, 16, 487-494 (1995).
6. FESTENSTEIN, H. and DEMANT, P., HLA and H-2. Basic immunogenetics, biology, and clinical relevance. E. Arnold, London (1978).
7. GARRIDO, F., RUIZ-CABELLO, F., CABRERA, T., PEREZ-VILLAR, J.J., LOPEZ-BOTET, M., DUGGAN-KEEN, M. and STERN, P.L., Implications for immuno-surveillance of altered HLA class I phenotypes in human tumours. Immunol. Today, 18, 89-95 (1997).
8. GUY, C.T., WEBSTER, M.A., SCHALLER, M., PARSONS, T.J., CARDIFF, R.D. and MULLER, W.J., Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. nat. Acad. Sci. (Wash.), 89, 10578-10582 (1992).
9. HASENKRUG, K.J., CORY, J.M. and STIMPFLING, J.H., Monoclonal antibodies defining mouse tissue antigens encoded by the H-2 region. Immunogenetics, 25, 136-139 (1987).
10. JULIUS, M.H., SIMPSON, E. and HERZENBERG, L.A., A rapid method for the isolation of functional thymus-derived murine lymphocytes. Europ. J. Immunol., 3, 645-649 (1973).
11. + T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression. Int. J. Cancer, 70, 112-119 (1997).
12. MARTH, C., MUELLER-HOLZNER, E., GREITER, E., CRONAUER, M.V., ZEIMET, A.G., DOPPLER, W., EIBL, B., HYNES, N.E. and DAXENBICHLER, G., Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res., 50, 7037-7041 (1990).
13. MUNN, R.J., WEBSTER, M., MULLER, W.J. and CARDIFF, R.D., Histopathology of transgenic mouse mammary tumors (a short atlas). Semin. Cancer Biol., 6, 153-158 (1995).
14. NANNI, P., DE GIOVANNI, C., NICOLETTI, G., LANDUZZI, L., ROSSI, I., FRABETTI, F., GIOVARELLI, M., FORNI, G., CAVALLO, F., DI CARLO, E., MUSIANI, P. and LOLLINI, P.-L., The immune response elicited by mammary adenocarcinoma cells transduced with gamma-interferon and cytosine deaminase genes cures lung metastases by parental cells. Hum. Gene Ther., 9, 217-224 (1998).
15. NICOLETTL, G., DE GIOVANNI, C., LOLLINI, P.-L., BAGNARA, G.P, SCOTLANDI, K., LANDUZZI, L., DEL RE, B., ZAULI, G., PRODI, G. and NANNI, P., In vivo and in vitro production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. Europ. J. Cancer clin. Oncol., 25, 1281-1286 (1989).
16. NISTICÓ, P., MOTTOLESE, M., MAMMI, C., BENEVOLO, M., DEL BELLO, D., RUBIU, O., GENTILE, F.P., BOTTI, C., VENTURO, I. and NATALI, P.G., Low frequency of ErbB-2 proto-oncogene overexpression in human leukocyte antigen-A2-positive breast cancer patients. J. nat. Cancer Inst., 89, 319-321 (1997).
17. OZATO, K., MAYER, N.M. and SACHS, D.H., Monoclonal antibodies to mouse major histocompatibility complex antigens. IV. A series of hybridoma clones producing anti-H-2d antibodies and an examination of expression of H-2d antigens on the surface of these cells. Transplantation, 34, 113-120 (1982).
18. SICA, G., ANGELUCCI, C., MARINI, L., MILAZZO, F. and DONINI, S., Oncogene expression is modulated by recombinant human interferon-beta in human breast cancer cells. Int. J. Cancer, 67, 441-446 (1996).
19. SLAMON, D.J., CLARCK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH., A. and MCGUIRE, W.L., Human breast cancer: correlation of relapse an survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182 (1987).
20. SQUARTINI, F., Tumours of the mammary gland. In: V.S. Turusov (ed.), Pathology of tumours in laboratory animal. Vol. II. Tumours of the mouse. IARC Scientific Publications, Lyon, France (1979).
21. TAYLOR, P., GERDER, M., MOROS, Z. and FELDMANN, M., Humoral and cellular responses against the human HER2 oncoprotein are cross-reactive with the homologous product of the neu proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu. Cancer Immunol. Immunother., 42, 179-184 (1996).